newsfilter
← Latest News
GlobeNewswire·

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

No dose-limiting toxicities or concerning side effects in our Phase 1/2 study with ONCT-534, our dual-action androgen receptor inhibitor (DAARI), for patients with advanced prostate cancer who are resistant to approved